Prostate cancer, version 1.2016: Featured updates to the NCCN guidelines

James L. Mohler; Andrew J. Armstrong; Robert R. Bahnson; Anthony Victor D'Amico; Brian J. Davis; James A. Eastham; Charles A. Enke; Thomas A. Farrington; Celestia S. Higano; Eric M. Horwitz; Michael Hurwitz; Christopher J. Kane; Mark H. Kawachi; Michael Kuettel; Richard J. Lee; Joshua J. Meeks; David F. Penson; Elizabeth R. Plimack; Julio M. Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Stan Rosenfeld; Edward Schaeffer; Ted A. Skolarus; Eric J. Small; Guru Sonpavde; Sandy Srinivas; Seth A. Strope; Jonathan Tward; Dorothy A. Shead; Deborah A. Freedman-Cass

doi:10.6004/jnccn.2016.0004

Prostate cancer, version 1.2016: Featured updates to the NCCN guidelines

James L. Mohler
, Andrew J. Armstrong
, Robert R. Bahnson
, Anthony Victor D'Amico
, Brian J. Davis
, James A. Eastham
, Charles A. Enke
, Thomas A. Farrington
, Celestia S. Higano
, Eric M. Horwitz
, Michael Hurwitz
, Christopher J. Kane
, Mark H. Kawachi
, Michael Kuettel
, Richard J. Lee
, Joshua J. Meeks
, David F. Penson
, Elizabeth R. Plimack
, Julio M. Pow-Sang
, David Raben

Sylvia Richey, Mack Roach, Stan Rosenfeld, Edward Schaeffer, Ted A. Skolarus, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, Deborah A. Freedman-Cass

Department of Urology

Duke University
Ohio State University
Dana-Farber/Brigham and Women's Cancer Center
Mayo Clinic Rochester, MN
Memorial Sloan-Kettering Cancer Center
University of Nebraska Medical Center
Prostate Health Education Network (PHEN)
Seattle Cancer Care Alliance
Fox Chase Cancer Center
Yale University
University of California at San Diego
City of Hope National Med Center
Roswell Park Cancer Institute
Massachusetts General Hospital Cancer Center
Northwestern University
Vanderbilt University
Moffitt Cancer Center
University of Colorado Cancer Center
University of Tennessee Health Science Center
University of California at San Francisco
Johns Hopkins University
University of Michigan, Ann Arbor
University of Alabama at Birmingham
Stanford University
Washington University St. Louis
University of Utah
National Comprehensive Cancer Network

Research output: Contribution to journal › Article › peer-review

583 Scopus citations

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.

Original language	English
Pages (from-to)	19-30
Number of pages	12
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	14
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2016.0004
State	Published - Jan 1 2016

Access to Document

10.6004/jnccn.2016.0004

Cite this

Mohler, J. L., Armstrong, A. J., Bahnson, R. R., D'Amico, A. V., Davis, B. J., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., Hurwitz, M., Kane, C. J., Kawachi, M. H., Kuettel, M., Lee, R. J., Meeks, J. J., Penson, D. F., Plimack, E. R., Pow-Sang, J. M., ... Freedman-Cass, D. A. (2016). Prostate cancer, version 1.2016: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 14(1), 19-30. https://doi.org/10.6004/jnccn.2016.0004

@article{3e2aec1991c34c6a93c40dd595301142,

title = "Prostate cancer, version 1.2016: Featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-na{\"i}ve disease.",

author = "Mohler, \{James L.\} and Armstrong, \{Andrew J.\} and Bahnson, \{Robert R.\} and D'Amico, \{Anthony Victor\} and Davis, \{Brian J.\} and Eastham, \{James A.\} and Enke, \{Charles A.\} and Farrington, \{Thomas A.\} and Higano, \{Celestia S.\} and Horwitz, \{Eric M.\} and Michael Hurwitz and Kane, \{Christopher J.\} and Kawachi, \{Mark H.\} and Michael Kuettel and Lee, \{Richard J.\} and Meeks, \{Joshua J.\} and Penson, \{David F.\} and Plimack, \{Elizabeth R.\} and Pow-Sang, \{Julio M.\} and David Raben and Sylvia Richey and Mack Roach and Stan Rosenfeld and Edward Schaeffer and Skolarus, \{Ted A.\} and Small, \{Eric J.\} and Guru Sonpavde and Sandy Srinivas and Strope, \{Seth A.\} and Jonathan Tward and Shead, \{Dorothy A.\} and Freedman-Cass, \{Deborah A.\}",

note = "Publisher Copyright: {\textcopyright} 2016 JNCCN-Journal of the National Comprehensive Cancer Network.",

year = "2016",

month = jan,

day = "1",

doi = "10.6004/jnccn.2016.0004",

language = "English",

volume = "14",

pages = "19--30",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "1",

}

Mohler, JL, Armstrong, AJ, Bahnson, RR, D'Amico, AV, Davis, BJ, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Hurwitz, M, Kane, CJ, Kawachi, MH, Kuettel, M, Lee, RJ, Meeks, JJ, Penson, DF, Plimack, ER, Pow-Sang, JM, Raben, D, Richey, S, Roach, M, Rosenfeld, S, Schaeffer, E, Skolarus, TA, Small, EJ, Sonpavde, G, Srinivas, S, Strope, SA, Tward, J, Shead, DA & Freedman-Cass, DA 2016, 'Prostate cancer, version 1.2016: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 1, pp. 19-30. https://doi.org/10.6004/jnccn.2016.0004

TY - JOUR

T1 - Prostate cancer, version 1.2016

T2 - Featured updates to the NCCN guidelines

AU - Mohler, James L.

AU - Armstrong, Andrew J.

AU - Bahnson, Robert R.

AU - D'Amico, Anthony Victor

AU - Davis, Brian J.

AU - Eastham, James A.

AU - Enke, Charles A.

AU - Farrington, Thomas A.

AU - Higano, Celestia S.

AU - Horwitz, Eric M.

AU - Hurwitz, Michael

AU - Kane, Christopher J.

AU - Kawachi, Mark H.

AU - Kuettel, Michael

AU - Lee, Richard J.

AU - Meeks, Joshua J.

AU - Penson, David F.

AU - Plimack, Elizabeth R.

AU - Pow-Sang, Julio M.

AU - Raben, David

AU - Richey, Sylvia

AU - Roach, Mack

AU - Rosenfeld, Stan

AU - Schaeffer, Edward

AU - Skolarus, Ted A.

AU - Small, Eric J.

AU - Sonpavde, Guru

AU - Srinivas, Sandy

AU - Strope, Seth A.

AU - Tward, Jonathan

AU - Shead, Dorothy A.

AU - Freedman-Cass, Deborah A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.

AB - The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.

UR - https://www.scopus.com/pages/publications/84969516736

U2 - 10.6004/jnccn.2016.0004

DO - 10.6004/jnccn.2016.0004

M3 - Article

C2 - 26733552

AN - SCOPUS:84969516736

SN - 1540-1405

VL - 14

SP - 19

EP - 30

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -

Prostate cancer, version 1.2016: Featured updates to the NCCN guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this